Artelo Biosciences, Inc. ARTL
Artelo Biosciences, Inc. (Nasdaq: ARTL) is an oncology drug developer. Its lead program, ART27.13, is in Phase 2 for cancer-related anorexia/cachexia.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ART27.13 | cancer-related anorexia | small molecule | Phase 2 |
| ART26.12 | chemotherapy-induced peripheral neuropathy | small molecule | Phase 1 |
| ART12.11 | anxiety disorders, rare/orphan diseases | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.